Featured Research

from universities, journals, and other organizations

Maternal Deaths Following Cesarean Delivery Can Be Reduced

Date:
August 5, 2008
Source:
Elsevier Health Sciences
Summary:
Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further? A new study examined all maternal deaths in nearly 1.5 million birth records from the last six years to look for possible keys to saving more mothers. The study demonstrated that the risk of death attributable to cesarean delivery, approximately 2/100,000 procedures, can realistically be reduced only with universal thromboembolism prophylaxis for patients delivered by cesarean.

Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?

In a study published in the July 2008 issue of the American Journal of Obstetrics & Gynecology, researchers examined all maternal deaths in nearly 1.5 million birth records from the last 6 years to look for possible keys to saving more mothers. The study demonstrated that the risk of death attributable to cesarean delivery, approximately 2/100,000 procedures, can realistically be reduced only with universal thromboembolism prophylaxis for patients delivered by cesarean.

The study identified 95 maternal deaths among 1,461,270 births (6.5/100,000 births). Leading causes of death were complications of preeclampsia, amniotic fluid embolism, obstetric hemorrhage, cardiac disease, and pulmonary thromboembolism.

The risk of death causally related to cesarean delivery is approximately 2/100,000 cesareans vs 0.2/100,000 deaths caused by vaginal birth. This statistically significant difference (P<.001) translates into approximately 20 US deaths caused by cesarean delivery annually.

Nine patients died from pulmonary thromboembolism, 7 after cesarean delivery and 2 after vaginal birth. None had received peripartum thromboembolism prophylaxis in the form of either fractionated or unfractionated heparin or pneumatic compression devices.

Writing in the article, Steven L. Clark, MD, Medical Director of the Women and Newborns Clinical Program, Hospital Corporation of America, states, "In nearly every population of adult surgical patients, either medical or mechanical thromboprophylaxis reduces venous thromboembolism by approximately 70%...If one assumes similar efficacy in pregnant women, 5 of the 7 deaths from pulmonary embolism in women undergoing cesarean delivery would have been prevented if a policy of universal use of medical or mechanical thromboprophylaxis for patients undergoing cesarean had been in place. Such a policy would reduce the mortality rate attributed causally to cesarean delivery to 0.9/100,000, or approximately 9 US deaths annually, eliminating the statistical difference in deaths attributed to cesarean vs. vaginal birth." Dr. Clark notes that the Hospital Corporation of American has instituted such a policy to improved patient safety throughout their system, the largest in the United States.

Dr. Clark continues, "It seems clear that the majority of maternal deaths in the United States are not preventable. The most common preventable errors in preeclampsia management leading to maternal death involved inattention to blood pressure control and signs or symptoms of pulmonary edema; those involving postpartum hemorrhage deaths were related to inadequate surgical hemostasis. In all these cases, more prompt attention to clinical signs of hemorrhage and associated hypovolemia would also have prevented death."


Story Source:

The above story is based on materials provided by Elsevier Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Steven Clark, MD; Michael Belfort, MD; Gary Dildy, MD; Melissa Herbst, MD; Janet A. Meyers, RN; and Gary Hankins, MD. Maternal Death in the 21st Century: Causes, Prevention and Relationship to Cesarean Delivery. American Journal of Obstetrics & Gynecology, Volume 199, Issue 1 (July 2008)

Cite This Page:

Elsevier Health Sciences. "Maternal Deaths Following Cesarean Delivery Can Be Reduced." ScienceDaily. ScienceDaily, 5 August 2008. <www.sciencedaily.com/releases/2008/08/080804100256.htm>.
Elsevier Health Sciences. (2008, August 5). Maternal Deaths Following Cesarean Delivery Can Be Reduced. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/08/080804100256.htm
Elsevier Health Sciences. "Maternal Deaths Following Cesarean Delivery Can Be Reduced." ScienceDaily. www.sciencedaily.com/releases/2008/08/080804100256.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins